A Phase 3 interventional study of adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 5 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-26.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 54th largest by enrollment, is one of 7 that started in 2007, is one of 36 in phase 3, and was the 40th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2007, is one of 14 in phase 3, and was the 33rd registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available for participants not receiving concomitant disease-modifying antirheumatic drugs (DMARDs) who did not achieve American College of Rheumatology 20 (ACR20) criteria after 12 weeks of treatment. Efficacy and safety measurements were performed throughout the study.
This is an open-label, multicenter study designed to establish the safety and efficacy of adalimumab in the treatment of moderate to severely active rheumatoid arthritis. A total of 100 subjects with inadequate preexisting standard anti-rheumatic therapy were enrolled at 5 sites in Russia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subject is either not of childbearing potential, defined as (at least 1 year since last menses) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of throughout the study and for 150 days after study completion:
Subjects must meet the following three criteria:
Exclusion Criteria:
Screening clinical laboratory analysis showing any of the following abnormal laboratory results:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab / pre-filled syringe 40 mg/0.8 ml
Drug: adalimumab
Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
Also known as: ABT-D2E7, Humira
Frequency of Adverse Events
Serious adverse events were collected from the time of informed consent, and nonserious adverse events were collected from the time of first dose of adalimumab, until 70 days after the last injection of adalimumab. Refer to the Reported Adverse Events section of this results disclosure for specific adverse events reported. Note: Severe events considerably interfered in patients' usual activities and may have been life-threatening. Serious events were life-threatening; resulted in hospitalization, congenital anomalies, or disability; or required intervention to prevent seriousness.
Time frame: Up to 34 weeks (24 week study treatment plus 70-day follow-up period)
Changes of Physical Examination
Physical examination findings were compared between Baseline and Week 24, and changes were recorded (Normal at Baseline to Abnormal at Week 24; or Abnormal at Baseline to Normal at Week 24). Physical examination criteria (normal vs. abnormal) were at the clinical judgement of the examining physician. Significant changes in physical examination from Baseline were considered to be adverse events.
Time frame: Baseline and 24 weeks
Deviation From Normal Laboratory Ranges
Laboratory values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note abbreviations used in table: Alk. phosphatase = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ESR = erythrocyte sedimentation rate
Time frame: 24 weeks
Vital Sign Values
Vital signs values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note, in table, BP = blood pressure.
Time frame: 24 weeks
Change in Disease Activity Score (DAS28) Compared With Baseline
The DAS28 is validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health (patient's global assessment of disease activity) were included in the DAS28 score. Scores on the DAS28 range from 1 (inactive disease) to 10 (very active disease).
Time frame: Baseline and 24 weeks
| Milestone | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Started | 100 |
| Completed | 95 |
| Not completed | 5 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 2 |
Serious adverse events were collected from the time of informed consent, and nonserious adverse events were collected from the time of first dose of adalimumab, until 70 days after the last injection of adalimumab. Refer to the Reported Adverse Events section of this results disclosure for specific adverse events reported. Note: Severe events considerably interfered in patients' usual activities and may have been life-threatening. Serious events were life-threatening; resulted in hospitalization, congenital anomalies, or disability; or required intervention to prevent seriousness.
| participants | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Adverse events | 38 |
| Serious adverse events | 1 |
| Severe adverse events | 1 |
| Possibly or probably related to adalimumab | 24 |
| Adverse events leading to discontinuation | 3 |
| Fatal adverse events | 0 |
Physical examination findings were compared between Baseline and Week 24, and changes were recorded (Normal at Baseline to Abnormal at Week 24; or Abnormal at Baseline to Normal at Week 24). Physical examination criteria (normal vs. abnormal) were at the clinical judgement of the examining physician. Significant changes in physical examination from Baseline were considered to be adverse events.
| participants | Change From Normal to Abnormal | Change From Abnormal to Normal |
|---|---|---|
| General Appearance | 0 | 0 |
| Head | 0 | 0 |
| Ears | 0 | 0 |
| Eyes | 1 | 0 |
| Nose | 0 | 0 |
| Throat | 0 | 0 |
| Neck | 0 | 0 |
| Thyroid | 0 | 0 |
| Lungs/Chest | 0 | 0 |
| Cardiovascular | 1 | 0 |
| Abdomen | 0 | 0 |
| Musculoskeletal | 0 | 0 |
| Extremities | 0 | 0 |
| Skin | 0 | 1 |
| Lymph nodes | 1 | 1 |
| Neurological | 0 | 0 |
| Genitourinary | 0 | 0 |
| Other | 0 | 0 |
Laboratory values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note abbreviations used in table: Alk. phosphatase = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ESR = erythrocyte sedimentation rate
| participants | Below Reference Range | Above Reference Range |
|---|---|---|
| Basophils (%) (ref. range: 0% - 1%) (n = 95) | 0 | 0 |
| Basophils (ref. range 0 - 2 x 10^9/L) (n = 94) | 0 | 0 |
| Eosinophils (%) (ref. range 1% - 5%) (n = 95) | 17 | 11 |
| Eosinophils (ref. range 0 - 1 x 10^9/L) (n = 94) | 0 | 0 |
| Erythrocytes (ref. range 4 - 5 x 10^12/L) (n = 95) | 15 | 9 |
| ESR (ref. range 0 - 30 mm/h) (n = 75) | 0 | 14 |
| Hematocrit (ref. range 35% - 47%) (n = 95) | 15 | 2 |
| Hemoglobin (ref. range 12 - 16 g/dL) (n = 95) | 33 | 1 |
| Leucocytes (ref. range 4 - 11 x 10^3/L) (n = 95) | 3 | 10 |
| Lymphocytes (%) (ref. range 19% - 37%) (n = 95) | 15 | 24 |
| Lymphocytes (ref. range 2 - 4 x 10^9/L) (n = 94) | 44 | 6 |
| Monocytes (%) (ref. range 3% - 11%) (n = 95) | 1 | 12 |
| Monocytes (ref. range 0 - 1 x 10^9/L) (n = 94) | 0 | 6 |
| Neutrophils (%) (ref. range 48% - 78%) (n = 95) | 20 | 6 |
| Neutrophils (ref. range 2 - 9 x 10^9/L) (n = 95) | 5 | 3 |
| Platelets (ref. range 150-400 x 10^3/mcL) (n = 95) | 0 | 9 |
| Albumin (ref. range 35 - 50 g/L) (n = 97) | 0 | 14 |
| Alk. phosphatase (ref. range 40-150 U/L) (n = 97) | 1 | 2 |
| ALT (ref. range 0 - 31 U/L) (n = 97) | 0 | 9 |
| AST (ref. range 0 - 31 U/L) (n = 97) | 0 | 6 |
| Calcium (ref. range 2 - 3 mmol/L) (n = 97) | 1 | 0 |
| Chloride (ref. range 98 - 107 mEq/L) (n = 96) | 0 | 0 |
| Creatine kinase (ref. range 0 - 167 U/L) (n = 97) | 0 | 2 |
| Creatinine (ref. range 53 - 97 mcmol/L) (n = 97) | 1 | 1 |
| C-reactive protein (ref. range 0-5 mg/L) (n = 97) | 0 | 45 |
| Glucose (ref. range 4- 6 mmol/L) (n = 97) | 4 | 10 |
| Potassium (ref. range 4 - 6 mmol/L) (n = 97) | 21 | 0 |
| Sodium (ref. range 136 - 145 mmol/L) (n = 97) | 2 | 0 |
| Total bilirubin (ref. range 3-20 mcmol/L) (n = 97) | 0 | 5 |
| Total cholesterol (ref. range 4-8 mmol/L) (n = 97) | 5 | 4 |
| Total protein (ref. range 64-83 g/L) (n = 97) | 3 | 2 |
| Urea (ref. range 2 - 6 mmol/L) (n = 96) | 0 | 30 |
| Urea nitrogen (ref. range 6 - 20 mg/dL) (n = 97) | 0 | 11 |
| Uric acid (ref. range 150 - 350 mcmol/L) (n = 97) | 11 | 6 |
| Urine pH (ref. range 5 - 8) (n = 98) | 0 | 1 |
Vital signs values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note, in table, BP = blood pressure.
| participants | Below Reference Range | Above Reference Range |
|---|---|---|
| Systolic BP (ref. range 100 - 140 mm Hg) | 1 | 2 |
| Diastolic BP (ref. range 60 - 100 mm Hg) | 0 | 0 |
| Pulse (ref. range 50 - 90 beats/min) | 0 | 0 |
| Body temperature (ref. range 36 - 37 degrees C) | 1 | 0 |
The DAS28 is validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health (patient's global assessment of disease activity) were included in the DAS28 score. Scores on the DAS28 range from 1 (inactive disease) to 10 (very active disease).
| units on a scale | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Change in Disease Activity Score (DAS28) Compared With Baseline | -2.74 ± 1.18 |
Collected over Adverse events were collected from the time of informed consent up to 70 days after the last injection of adalimumab.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL | — | 1/100 (1%) | 38/100 (38%) |
| Event | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Pyogenic arthritisInfections and infestations | 1/100 |
| Event | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| NasopharyngitisInfections and infestations | 4/100 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 4/100 |
| HeadacheNervous system disorders | 3/100 |
| Injection site erythemaGeneral disorders | 3/100 |
| OsteochondrosisMusculoskeletal and connective tissue disorders | 3/100 |
| Respiratory tract infection viralInfections and infestations | 3/100 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 3/100 |
| Back painMusculoskeletal and connective tissue disorders | 2/100 |
| Body temperature increasedInvestigations | 2/100 |
| Injection site pruritusGeneral disorders | 2/100 |
| Age, Categorical(Participants) | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 90 |
| >=65 years | 10 |
| Age Continuous(years) | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Mean | 50.9 ± 11.1 |
| Sex: Female, Male(Participants) | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Female | 89 |
| Male | 11 |
| Region of Enrollment(participants) | Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL |
|---|---|
| Russian Federation | 100 |
The record gives a start of Dec 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab